SCHEMBL19087149

SCHEMBL19087149

Cc1cnn(Cc2ccc(C(=O)O)cc2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.70
KLKB1 P03952 10/20 0.56
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 3/20 0.53
POLB P06746 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MEN1 O00255 1/20 0.53
USP2 O75604 1/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
THRB P10828 1/20 0.53
NR4A1 P22736 1/20 0.53
APEX1 P27695 1/20 0.53
APOBEC3A P31941 1/20 0.53
RECQL P46063 1/20 0.53
KMT2A Q03164 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HIF1A Q16665 1/20 0.53
APOBEC3G Q9HC16 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16246805 0.92 KLKB1 (0.62) HSD17B10KLKB1ALDH1A1KDM4EPOLB
SCHEMBL16487112 0.86 HSD17B10 (0.53) HSD17B10KLKB1POLBTDP1L3MBTL1
SCHEMBL1912400 0.85 HSD17B10 (0.77) HSD17B10KLKB1ALDH1A1KDM4EPOLB
SCHEMBL948453 0.84 HSD17B10 (0.61) HSD17B10KLKB1ALDH1A1KDM4EPOLB
SCHEMBL17221323 0.84 KLKB1 (0.56) HSD17B10KLKB1ALDH1A1KDM4ETDP1
SCHEMBL28047272 0.84 KLKB1 (0.65) HSD17B10KLKB1
SCHEMBL19117032 0.83 HSD17B10 (0.68) HSD17B10ALDH1A1KDM4EPOLBTDP1
SCHEMBL27286142 0.83 HSD17B10 (0.68) HSD17B10KLKB1ALDH1A1KDM4EPOLB
SCHEMBL28052880 0.83 KLKB1 (0.52) HSD17B10KLKB1POLBTDP1L3MBTL1
SCHEMBL16486491 0.83 KLKB1 (0.63) HSD17B10KLKB1POLBTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024026481-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
EP-3792256-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2021-03-17 EP disclosed
EP-3400221-B1 PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS INCYTE CORP (US) 2020-08-26 EP disclosed
WO-2017120194-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2017-07-13 WO disclosed
US-20170190689-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190689-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS PIK3CG, PIK3CD, PIK3CB HSD17B10 3403/4885KLKB1 3723/4885ALDH1A1 2997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.